Saturday, 21 November 2026
M
Meridian Globe
Live briefing
[Editorial] Multiple sclerosis: beyond controlling relapses— 柳叶刀 Lancet[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?— 柳叶刀 Lancet[Comment] Expanding the post-EGFR TKI landscape with antibody–drug conjugates— 柳叶刀 Lancet[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer— 柳叶刀 Lancet[Comment] Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother— 柳叶刀 Lancet[Comment] Offline: A manifesto for protecting public health— 柳叶刀 Lancet[World Report] Türkiye's coal industry draws criticism— 柳叶刀 Lancet[World Report] Research Focus: Te Poutoko Ora a Kiwa (Centre for Pacific and Global Health)— 柳叶刀 Lancet[Editorial] Multiple sclerosis: beyond controlling relapses— 柳叶刀 Lancet[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?— 柳叶刀 Lancet[Comment] Expanding the post-EGFR TKI landscape with antibody–drug conjugates— 柳叶刀 Lancet[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer— 柳叶刀 Lancet[Comment] Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother— 柳叶刀 Lancet[Comment] Offline: A manifesto for protecting public health— 柳叶刀 Lancet[World Report] Türkiye's coal industry draws criticism— 柳叶刀 Lancet[World Report] Research Focus: Te Poutoko Ora a Kiwa (Centre for Pacific and Global Health)— 柳叶刀 Lancet

Can Anthropic’s IPO do for the stock market what Nvidia’s earnings couldn’t?

Source MarketWatch 财经1d ago
Summary

Here’s the case for energy stocks in your 401(k) and why Target’s comeback runs through the shoe aisle. Plus, what “GTA VI” means for Take-Two investors.

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Business
Region
Americas
Language
English
Item ID
business-069ce9f0

Comments 0 comments

No comments yet. Be the first.

Can Anthropic’s IPO do for the stock market what Nvidia’s earnings couldn’t? · Meridian Globe